Home > GAMMAGARD Products > GAMMAGARD LIQUID IV > Tolerability

Tolerability
GAMMAGARD LIQUID - IV Administration

Protecting life’s moments with an established tolerability profile1


 
(381/400) of non-serious adverse reactions (ARs) reported in this study were considered mild (217) or moderate (164).
(The remaining 5% [19/400] were rated severe)
 
of non-serious ARs were mild (n=217)
Mild ARs were defined as transient discomfort that resolves spontaneously or with minimal intervention
 
of non-serious ARS were moderate (n=164)
Moderate ARs were defined as limited impairment of function that resolves spontaneously or with minimal intervention with no sequelae
 
of non-serious ARs were severe (n=19)
All 19 severe ARs resolved without complications or hospitalization
Severe ARs were defined as marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae

 
  • One subject withdrew from the study due to a non-serious adverse experience (papular rash)
  • Fifteen adverse reactions in 8 subjects were serious. Of these, two episodes of aseptic meningitis in one patient were deemed possibly related to the infusion of GAMMAGARD LIQUID

Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation. April 2014.


  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Choosing IV or SC Which is the right choice for your patient? Compare the differences using our chart.
    Take a Look
  • Insurance Assistance For access to experts who can provide expedited benefits verification and other insurance coverage resources, call 1-855-250-5111.

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to
GAMMAGARD.com
Continue